End Price Gouging for Medications Act
Rep. Dingell Introduces End Price Gouging for Medications Act to Cap Drug Prices at International Levels
This bill is currently in the early stages of the legislative process and is being reviewed by a subcommittee. It is actively moving through the committee system, but no further votes or hearings have been scheduled yet. There is no companion bill listed for this legislation at this time.
Legislative Progress
While lowering drug costs is popular with voters, this bill faces intense opposition from the pharmaceutical industry and lacks the bipartisan support needed to pass a divided Congress.
Key Points
Impact Analysis
Personal Impact
Life & Work
Small businesses that provide group health insurance to employees would benefit from lower drug costs, which are a major driver of rising premiums. The reference pricing requirement applies to all group health plans, so the savings would flow through to smaller employers who often struggle most with healthcare costs.
Programs
Disabilities
Milestones
Referred to the Subcommittee on Health.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Armed Services, Veterans' Affairs, Oversight and Government Reform, and Natural Resources, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
Source Information
Document Type
Congressional Bill
Official Title
End Price Gouging for Medications Act
Data Sources
Sponsor
Cosponsors
(1)Analysis generated by AI. Always verify with official sources.